Title : Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.

Pub. Date : 2021 Mar 18

PMID : 33737682






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. pladienolide B erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC. pladienolide B erb-b2 receptor tyrosine kinase 2 Homo sapiens